TAXOTERE 20 mg/ml
 |
|
|
Package(a):
VIAL: 1 x 20 mg/1 ml.
Dosage(a):
According to indication. See prescribing information for full details.
Prescribing Restrictions: None
Package(b):
VIAL: 1 x 80mg/4 ml.
Dosage(b):
According to indication. See prescribing information for full details.
Prescribing Restrictions: None
Indications:
Breast cancer: In combination with doxorubicin and cyclophosphamide for the adjuvant treatment of patients with operable node- positive breast cancer. In combination with doxorubicin for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. In combination with trastuzumab for the treatment of patients with metastatic breast cancer whose tumors overexpress HER2 and who previously have not received chemotherapy for metastatic disease. In combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Doxorubicin and cyclophosphamide followed by Taxotere in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. In combination with trastuzumab, and carboplatin (TCH) for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. As monotherapy for the treatment of patients metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.
Non-small cell lung cancer: Treatment of patients with advanced non-small cell lung carcinoma.
Ovarian Cancer: Treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.
Prostate cancer: In combination with prednisone or prednisolone for the treatment of patients with hormone refractory metastatic prostate cancer.
Esophageal cancer: Treatment of esophageal cancer.
Gastric cancer: Treatment of advanced gastric cancer.
Head and neck (SCCHN) Monotherapy: Treatment of recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. Combination therapy: In combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of locally advanced squamous cell carcinoma of the head and neck.
Contra-Indications:
Hypersensitivity to the active substance or to any of the excipients. Patients with baseline neutrophil count of <1,500 cells/mm
3. Patients with severe liver impairment. Contraindications for other medicinal products also apply, when combined with docetaxel. See prescribing information for full details.
Special Precautions:
See prescribing information for full details.
Side Effects:
See prescribing information for full details.
Drug Interactions:
See prescribing information for full details.
